Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings.
Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while the S&P 500 futures was up 0.
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session,
Abbott’s (ABT) Impressive Q4 and Bold Projections for 2025: What You Need to Know
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 and $1.09, further underscoring its momentum heading into the new year.
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks Consensus Estimate. However, the figure improved 12.6% from the prior-year quarter’s level.
Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales
For full-year 2025, the company forecast organic sales growth between 7.5% and 8.5% as well as adjusted earnings per share in the range of $5.05 and $5.25. Analysts polled by FactSet expect $42 billion in sales and adjusted earnings of $5.16 a share.
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong performance in medical devices.
Abbott Laboratories Q4 Profit Increases, Inline With Estimates
Abbott Laboratories (ABT) revealed a profit for its fourth quarter that increased from last year in line with the Street estimates.
Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit
Abbott stock fell early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported in-line profit.
Abbott (ABT) Q4 Earnings Meet Estimates
Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items.
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott Banks on Glucose Monitors, New Launches to Ride Out China, Currency Hit
(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Abbott Laboratories: Strong Performance and Promising Outlook Support Buy Rating
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Investor's Business Daily on MSN23h
Abbott Shrugs Off 'Middling' Quarter As 2025 Sales Guidance, Diabetes Tech Shine
Abbott stock reversed early losses Wednesday on its strong sales outlook for 2025 and a bullish performance from its diabetes ...